Hetero Ring Is Six-membered Consisting Of Three Nitrogens And Three Carbon Atoms Patents (Class 514/241)
-
Patent number: 7868177Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.Type: GrantFiled: February 21, 2007Date of Patent: January 11, 2011Assignee: Amgen Inc.Inventors: Victor J. Cee, Holly L. Deak, Stephanie D. Geuns-Meyer, Brian L. Hodous, Hanh Nho Nguyen, Philip R. Olivieri, Vinod F. Patel, Karina Romero
-
Publication number: 20100330166Abstract: An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects.Type: ApplicationFiled: January 29, 2009Publication date: December 30, 2010Applicants: The University of Tokushima, Taiho Pharmaceutical Co., Ltd.Inventors: Tatsuhiro Ishida, Hiroshi Kiwada
-
Publication number: 20100331310Abstract: Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R1, R2 and R3 represent hydrogen, etc., X1 represents C1-6 alkylene, etc., X2 represents C1-6 alkylene, etc., A1 represents a 5- to 6-membered heterocyclic group, etc., and A2 represents C6-14 aryl, etc.Type: ApplicationFiled: February 9, 2009Publication date: December 30, 2010Inventors: Fumihiro Ozaki, Motohiro Soejima, Tasuku Ishida, Yoshihiko Norimine, Nobuyuki Kurusu, Eriko Doi, Toshihiko Kaneko, Daiju Hasegawa, Kiyoaki Kobayashi, Noboru Yamamoto
-
Publication number: 20100323009Abstract: A solid composition in the form of a tablet that generates and releases a biocidal solution comprising at least chlorine dioxide with an enhanced weight percent yield is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide comprising a chlorite donor that is coated with a gel-forming material that slows the rate of dissolution of the high solubility chlorite donor, a free halogen donor, and an acid source, resulting in an unexpectedly high weight percent yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging and significantly increase the utility of the composition. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a controlled and sustained release.Type: ApplicationFiled: August 25, 2010Publication date: December 23, 2010Inventor: Roy W. Martin
-
Patent number: 7855194Abstract: This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.Type: GrantFiled: March 15, 2007Date of Patent: December 21, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Alfred Binggeli, Andreas Christ, Hans-Peter Maerki, Rainer Eugen Martin
-
Patent number: 7851622Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I where R1, R1a, R1b, A, R3, R4, R5, R5b and R6 are as defined herein.Type: GrantFiled: April 25, 2008Date of Patent: December 14, 2010Assignee: Bristol-Myers Squibb CompanyInventors: William N. Washburn, Saleem Ahmad, Andres S. Hernandez
-
Patent number: 7851517Abstract: A system, method and apparatus provices an antimicrobial card, badge holder or token made from an antimicrobial polymereric material. The antimicrobial polymereric material includes one or more polymers and one or more antimicrobial agents that affect the growth of bacteria, fungi, virus or a combination thereof.Type: GrantFiled: October 31, 2007Date of Patent: December 14, 2010Inventor: Lisa Marie Holmes
-
Publication number: 20100305132Abstract: Provided are biocidal compositions comprising glutaraldehyde and a compound selected from the group consisting of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane; tris(hydroxymethyl)-nitromethane; and a hexahydrotriazine compound. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.Type: ApplicationFiled: May 21, 2010Publication date: December 2, 2010Inventor: Bei Yin
-
Publication number: 20100305078Abstract: The presently disclosed subject matter is directed to metallo-oxidoreductase inhibitors having metal binding moities linked to a targeting moiety through a linking group or a direct bond, methods for screening for metallo-oxidoreductase inhibitors, and methods of treating an oxidoreductase related disorder by administering a metallo-oxidoreductase inhibitor to a subject in need of treatment thereof.Type: ApplicationFiled: November 21, 2007Publication date: December 2, 2010Applicant: Viamet Pharmaceuticals, Inc.Inventors: Robert J. Schotzinger, William J. Hoekstra
-
Publication number: 20100305124Abstract: The present invention relates to aminopyridine and aminopyridazine derivatives of the general formula (I) in which R1, X, W and Q have the definitions given in the description, to a number of processes for preparing them, and to their use as insecticides.Type: ApplicationFiled: April 2, 2010Publication date: December 2, 2010Applicant: BAYER CROPSCIENCE AGInventors: Martin FUSSLEIN, Ernst Rudolf Gesing, Markus Heil, Bernd Alig, Eva-Maria Franken, Olga Malsam, Arnd Voerste, Koichi Araki, Norio Sasaki, Sachio Kudo, Eiichi Shimojo, Teruyuki Ichihara, Masashi Ataka, Katsuhiko Shibuya
-
Patent number: 7842805Abstract: Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: July 3, 2007Date of Patent: November 30, 2010Assignees: Myrexis, Inc., EpiCept CorporationInventors: Sui Xiong Cai, Mark B. Anderson, Adam Willardsen, Songchun Jiang, Robert J. Halter, Rachel Slade, Yevgeniya Klimova
-
Patent number: 7838508Abstract: Compounds represented by the formula 1: A is selected from the group consisting of wherein each R individually is H or acyl, Y is X, N3, NH2, monoalkylamino, or dialkylamino; Z is O or S; and X is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, thioaryl, thioalkyl, allylamino, cyano and nitro; tautomers thereof; and pharmaceutically acceptable salts thereof are provided along with methods for their fabrication. Various of these compounds can be used as anticancer agents, or antiviral agents or to inhibit DNA replication.Type: GrantFiled: November 7, 2006Date of Patent: November 23, 2010Assignee: Southern Research InstituteInventors: John A. Secrist, III, Kamal N. Tiwari, John A. Montgomery, William L. Hinds, Jr., legal representative
-
Patent number: 7838520Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: March 15, 2005Date of Patent: November 23, 2010Assignee: MethylGene, Inc.Inventors: Daniel Delorme, Soon Hyung Woo, Arkadii Vaisburg, Oscar Moradei, Silvana Leit, Stephane Raeppel, Sylvie Frechette, Giliane Bouchain, Zhihong Zhou
-
Publication number: 20100292187Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.Type: ApplicationFiled: June 14, 2010Publication date: November 18, 2010Applicant: PTC THERAPEUTICS, INC.Inventors: Gary M. Karp, Peter Seongwoo Hwang, James J. Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony A. Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey A. Campbell, Chunshi Li, Steven Paget, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
-
Patent number: 7834007Abstract: The present invention encompasses compounds of Formula I which are antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.Type: GrantFiled: August 23, 2006Date of Patent: November 16, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Xiaojun Han, Prasad V. Chaturvedula
-
Patent number: 7825117Abstract: The present invention relates to prokineticin 1 receptor antagonists and methods of using the same to modulate intestine epithelial functions and to treat inflammation in the intestine in a mammal.Type: GrantFiled: June 27, 2006Date of Patent: November 2, 2010Inventors: John R. Mabus, Jeffrey M. Palmer, Stephen M. Prouty, Pamela J. Hornby, Paul R. Wade
-
Publication number: 20100273764Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.Type: ApplicationFiled: April 27, 2010Publication date: October 28, 2010Applicant: Amgen Inc.Inventors: Kristin Andrews, Yunxin Y. Bo, Shon Booker, Victor J. Cee, Noel D'Angelo, Bradley J. Herberich, Fang-Tsao Hong, Claire L.M. Jackson, Brian A. Lanman, Hongyu Liao, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian L. Smith, Seifu Tadesse, Nuria A. Tamayo, Bin Wu, Ryan Wurz, Kevin Yang
-
Publication number: 20100266706Abstract: An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative.Type: ApplicationFiled: December 26, 2008Publication date: October 21, 2010Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Yoshito Ohnishi, Tetsuo Ogata
-
Publication number: 20100261688Abstract: The invention relates to a stabilization of fluid oil-based suspensions comprising a hydrophobic silica, and medicaments based on such suspensions.Type: ApplicationFiled: November 12, 2008Publication date: October 14, 2010Applicant: BAYER ANIMAL HEALTH GMBHInventors: Iris Heep, Hans-Juergen Hamann, Sabine Koelling, Gert Daube, Klaus-Juergen Steffens, Rolf Daniels
-
Publication number: 20100249136Abstract: The invention concerns the use an mGluR modulator, e.g.Type: ApplicationFiled: October 9, 2008Publication date: September 30, 2010Inventors: Daniel Umbricht, Baltazar Gomez-Mancilla, Fabrizio Gasparini, Therese Di Paolo
-
Publication number: 20100240619Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1 N-oxides, and salts thereof, wherein R1, R2, A, G, W, Z1, X, J, and n are as defined in the disclosure, and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of the aforesaid composition. Also disclosed is a composition comprising component (a) of aforesaid composition and at least one insecticide. Also disclosed are compounds of Formula 1A, 1B and 1C, wherein R1, R2, A, G, W, Z1, X, J, n, Z3, M and J1 are as defined in the disclosure.Type: ApplicationFiled: October 23, 2008Publication date: September 23, 2010Inventors: Vann Gregory, Robert James Pasteris
-
Patent number: 7795255Abstract: Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.Type: GrantFiled: January 5, 2006Date of Patent: September 14, 2010Assignee: InSight Biopharmaceuticals Ltd.Inventors: Joel M. Van Gelder, Joseph Y. Klein, Yochai Basel, Anat Reizelman, Susanna Tchilibon, Orly Mouallem
-
Publication number: 20100227866Abstract: [Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). [Means for Solving Problems] It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.Type: ApplicationFiled: May 26, 2008Publication date: September 9, 2010Applicant: ASTELLAS PHARMA INC.Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
-
Patent number: 7790753Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: GrantFiled: April 17, 2006Date of Patent: September 7, 2010Assignee: sanofi-aventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Corinne Veronique
-
Publication number: 20100215643Abstract: Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.Type: ApplicationFiled: February 24, 2010Publication date: August 26, 2010Applicant: ORTHOBOND CORP.Inventors: Randell Clevenger, Jeffrey Schwartz
-
Patent number: 7776863Abstract: The invention encompasses pharmaceutical compositions and methods for using Compound 1 in combination with other agents for treating patients with AIDS or HIV infection.Type: GrantFiled: February 24, 2005Date of Patent: August 17, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Pin-Fang Lin, Beata Nowicka-Sans, Gregory Yamanaka
-
Publication number: 20100179151Abstract: The present invention relates to the transdermal application of triazines such as toltrazuril or ponazuril for controlling infections with coccidia in humans and animals.Type: ApplicationFiled: August 8, 2007Publication date: July 15, 2010Applicant: BAYER ANIMAL HEALTH GMBHInventors: Iris Heep, Hans-Christian Mundt
-
Patent number: 7750025Abstract: Compounds of formula (I) as defined herein: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine.Type: GrantFiled: April 17, 2006Date of Patent: July 6, 2010Assignee: sanofi-aventisInventors: Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat
-
Patent number: 7745440Abstract: One aspect of the invention is concerned with cannabimimetic pyrazole analogs. Another aspect of the invention is concerned with new and improved pyrazole analogs having high affinities and/or selectivities for the CB1 cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.Type: GrantFiled: October 6, 2005Date of Patent: June 29, 2010Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Qian Liu, Rajesh Thotapally
-
Publication number: 20100152168Abstract: The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.Type: ApplicationFiled: August 24, 2007Publication date: June 17, 2010Applicant: ABBOTT GMBH & CO. KGInventors: Torsten Arndt, Thorsten Oost, Wilfried Lubisch, Wolfgang Wernet, Wilfried Hornberger, Liliane Unger, Juliana Ruiz Caro
-
Patent number: 7732441Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both ?2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Such compounds are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.Type: GrantFiled: February 7, 2008Date of Patent: June 8, 2010Assignee: Theravance, Inc.Inventors: Mathai Mammen, Adam Hughes
-
Publication number: 20100137317Abstract: 1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.Type: ApplicationFiled: June 24, 2009Publication date: June 3, 2010Applicant: EnVivo Pharmaceuticals, Inc.Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
-
Publication number: 20100119620Abstract: A composition for anti-microbial effect in a water system such as a pulp and paper processing line with an aqueous slurry. The composition comprises a free chlorine-generating biocide comprising a chlorine source, urea, and an alkali in a concentration sufficient to provide a pH greater than 10, and typically at least pH 11.Type: ApplicationFiled: January 19, 2010Publication date: May 13, 2010Inventors: Laura E. Rice, Andrew J. Cooper, Robert L. Wetegrove, Michael V. Enzien
-
Publication number: 20100120773Abstract: The disclosure includes a method of treating a warm-blooded animal having a disorder mediated by the fibroblast growth factor receptor (FGFR), in particular 8p11 myelo-proliferative syndrome (EMS), pituitary tumors, retinoblastoma, synovial sarcoma, chronic obstructive pulmonary disease (COPD), seborrheic keratosis, obesity, diabetes and related disorders, autosomal dominant hypophosphatemic Rickets (ADHR), X-chromosome linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO) and fibrous dysplasia of the bone (FD), as well as to a method of promoting localized neochondrogenesis, as well as a method of treating hepatocellular carcinoma, lung cancer, especially pulmonary adnocarcinoma, oral squameous cell carcinoma, or esophageal squameous cell carcinoma, or any combination of two or more such diseases.Type: ApplicationFiled: January 14, 2010Publication date: May 13, 2010Inventors: Vito Guagnano, Diana Graus Porta
-
Publication number: 20100120714Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein W is O or S; V is a direct bond or NR3; Q is or CR6aR6b, O, NR7, C?N—O—R7 or C(?O); Y is —C(R5)?N—O—(CR8aR8b)p—X—(CR9aR9b)q—SiR10aR10bR10c; or a phenyl ring substituted as defined in the disclosure; or Z; and R1, R2, R3, R4, R5, R6a, R7, R8a, R8b, R9b, R10a, R10b, R10c, Z, p and q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.Type: ApplicationFiled: April 4, 2008Publication date: May 13, 2010Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: Bruce Lawrence Finkelstein, Andrew Edmund Taggi, Jefrey Keith Long, Paula Louise Sharpe, Chi-ping Tseng, Stephen Frederick Mccann, Amy X. Ding, Steven Lewis Swann, JR.
-
Patent number: 7700584Abstract: The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ?CHR2, —CH2R2, ?O, ?—OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmaceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.Type: GrantFiled: May 26, 2005Date of Patent: April 20, 2010Assignee: Hangzhou Minsheng Pharmaceuticals Co., Ltd.Inventors: Shulong Wang, Dianwu Guo, Zhaoke Meng
-
Patent number: 7700605Abstract: The invention relates to compounds of the formula I and salts thereof, to a process for their manufacture, to their use in the treatment of (especially cysteine protease, such as UCH-L3- and/or USP-2 dependent) diseases or for the manufacture of pharmaceutical formulations against these diseases, methods of treatment of warm-blooded animals comprising administering the compounds and/or their salts to said animals and pharmaceutical preparations, especially for the treatment of the diseases, comprising said compounds and/or salts.Type: GrantFiled: July 17, 2006Date of Patent: April 20, 2010Assignee: Novartis AGInventors: Stefanie Flohr, Pascal Furet, Patricia Imbach, Ulrich Hommel, Hans-Ulrich Litshcer, Shirley Gil Parrado, Ulrich Hassiepen, Johann Zimmermann
-
Publication number: 20100093736Abstract: Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I); wherein R1, R2, R3, R4, and R5 are as defined herein.Type: ApplicationFiled: December 13, 2007Publication date: April 15, 2010Applicants: ANGUS CHEMICAL COMPANY, DOW GLOBAL TECHNOLOGIES INC.Inventors: Charles E. Coburn, John L. Pohlman, Bonnie A. Pyzowski, Patrick E. Brutto, George David Green, Raymond J. Swedo
-
Publication number: 20100080857Abstract: Compositions comprising a mixture of (a) a major amount of solid halogen-containing sanitizer material and (b) a minor amount of calcium oxide modified particulate boric acid, the amount of calcium oxide modified particulate boric acid being sufficient to enable the composition to be classified as a class 1 or class 2 NFPA oxidizer are described. Also described is particulate boric acid at least a portion of the particles thereof having on their surface at least a partial coating of calcium oxide, and a method for preparing such coated particulate boric acid.Type: ApplicationFiled: September 30, 2008Publication date: April 1, 2010Applicant: PPG INDUSTRIES OHIO, INC.Inventor: Stanley R. Pickens
-
Publication number: 20100062069Abstract: A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein the spraying of whole of the solution occurs in at least two separate steps, each of these steps followed by a grinding step of the product obtained at the end of the preceding step.Type: ApplicationFiled: September 3, 2009Publication date: March 11, 2010Inventors: Gaël LAMOUREUX, Gérard Cousin, Daniel Joseph Christiaan Thoné
-
Patent number: 7666863Abstract: The present invention relates to benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.Type: GrantFiled: May 24, 2007Date of Patent: February 23, 2010Assignees: ViroPharma Incorporated, WYETHInventors: Ashis K. Saha, Christopher J Burns, Alfred M. Del Vecchio, Thomas R. Bailey, Jason A. Reinhardt, Bheemashankar A. Kulkarni, Thomas H. Faitg, Hao Feng, Susan R. Rippin, Charles W. Blackledge, David J. Rys, Thomas A. Lessen, John Swestock, Yijun Deng, Theodore J. Nitz
-
Patent number: 7662222Abstract: This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods.Type: GrantFiled: June 23, 2009Date of Patent: February 16, 2010Assignee: I-Tech ABInventors: Magnus Nydén, Camilla Fant
-
Publication number: 20100015250Abstract: An aqueous hydraulic fluid composition comprising of one or more lubricants such as a monovalent metal salt, ammonium, or alkanolamine salt of a dicarboxylic acid, such as a C21 dicarboxylic acid is described in which the aqueous hydraulic fluid composition demonstrates increased thermal stability when exposed to elevated temperatures for a prolonged period of time while being able to tolerate the presence of 10% v/v synthetic seawater. The aqueous hydraulic fluid composition contains less than about 20% by weight (preferably none or substantially none) of an oil selected from the group consisting of mineral oils, synthetic hydrocarbon oils, and mixtures thereof.Type: ApplicationFiled: July 15, 2008Publication date: January 21, 2010Inventor: Ian D. Smith
-
Publication number: 20100016313Abstract: Disclosed are modulators, i.e., activators and inhibitors, of Intestinal Alkaline Phosphatase (IAP). Also disclosed are methods for treating bacterial infections of the intestinal tract and methods for maintaining the health of the intestinal tract using IAP activators. Further disclosed are methods to assist in weight gain of emaciated patients and those having reduced or negligible fat absorption using IAP inhibitors.Type: ApplicationFiled: May 19, 2009Publication date: January 21, 2010Applicant: Burnham Institute for Medical ResearchInventors: Jose Luis Millan, Sonoko Narisawa, Eduard Sergienko
-
Publication number: 20100004244Abstract: The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-?-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for promoting, inducing and enhancing neurogenesis including neural cell regeneration. In particular, pharmaceutical compositions of the invention will be useful for preventing, alleviating or treating neurological injuries or damages to the CNS or the PNS associated with physical injury, ischemia, neurodegenerative disorders, certain medical procedures or medications, tumors, infections, metabolic or nutritional disorders, cognition or mood disorders, and various medical conditions associated with neural damage or destruction.Type: ApplicationFiled: June 27, 2007Publication date: January 7, 2010Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Ismael Galve-Roperh, Manuel Guzman, Raphael Mechoulam, Javier Palazuelos, Tania Aguado
-
Patent number: 7642255Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.Type: GrantFiled: April 8, 2008Date of Patent: January 5, 2010Assignee: IRM LLCInventors: Taebo Sim, Hyun Soo Lee, Pingda Ren, Qiang Ding, Yi Liu, Bing Li, Lintong Li, Xia Wang, Tetsuo Uno, Guobao Zhang, Nathanael Schiander Gray, Shuli You
-
Publication number: 20090325964Abstract: The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I: wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.Type: ApplicationFiled: May 22, 2009Publication date: December 31, 2009Applicant: WyethInventors: Matthew Gregory Bursavich, Adam Matthew Gilbert, Joseph Raymond Stock
-
Publication number: 20090318453Abstract: The invention provides a method for treatment of gastric cancer, which method is a postoperative adjuvant chemotherapy for gastric cancer, comprising orally administering, to a patient with gastric cancer in stage II, IIIA, or IIIB in a classification of the stage of gastric cancer, a pharmaceutical composition containing Tegafur, Gimeracil, and Oteracil potassium at a molar ratio of 1:0.4:1, at a dose of 50 to 150 mg/day as Tegafur dose and according to an administration schedule including, from within 45 days after a surgical operation of gastric cancer, drug administration for 28 consecutive days, followed by a rest period of 7 to 14 consecutive days. The chemotherapy reduces the relapse rate after a surgical operation, thereby improving the survival rate.Type: ApplicationFiled: September 20, 2007Publication date: December 24, 2009Applicant: TAIHO PHARMACEUTICAL CO., LTDInventor: Koichi Okabe
-
Publication number: 20090312330Abstract: An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof: wherein A1, A2 and A3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C1-C6haloalkyl, etc., Y is halogen atm, C1-C6alkyl, etc., R1 is C1-C12alkyl arbitrarily substituted with R16, C3-C12alkenyl, arbitrarily substituted with R16 is oxygen atom or sulfur atom, —N(R20)R19, etc., R2 is hydrogen atom, C1-C4alkoxy C1-C6alkyl, etc., R3 is C1-C6haloalkyl, etc., R16 is halogen atom, cyano, phenyl substituted with (Z)p1, D-1 to D-60, E-1 to E-49, etc., R19 is phenyl, phenyl substituted with (Z)p1, etc., R20 is hydrogen atom, C1-C6alkyl, etc., Z is halogen atom, nitro, C1-C4alkoxy, etc., D-1 to D-60 are 5- or 6-membered aromatic heterocyclic rings, E-1 to E-49 are 5- or 6-membered saturated heterocyclic rings, m is an integer of 0 to 5, n is an integer of 0 to 4, p1 is an integer of 1 to 5. The pesticide containing these compounds.Type: ApplicationFiled: July 27, 2009Publication date: December 17, 2009Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Takeshi Mita, Takamasa Kikuchi, Takashi Mizukoshi, Manabu Yaosaka, Mitsuaki Komoda
-
Patent number: 7622469Abstract: The present invention relates to an antibacterial agent, which comprises, as an active ingredient, a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 16, 2003Date of Patent: November 24, 2009Assignee: Hamari Chemicals, Ltd.Inventors: Shirou Maeda, Toshiko Kita, Kanji Meguro